SAB Biotherapeutics, Inc. (SAB BIO) has announced that Breakthrough T1D, a leading global type 1 diabetes (T1D) research and advocacy organization, has awarded a grant to support the PRISE-hATG clinical study. This study will evaluate SAB-142 in patients diagnosed with Stage 3 T1D between 100 days and two years prior. Stage 3 T1D is characterized by the need for insulin. The PRISE-hATG study aims to assess SAB-142's ability to preserve endogenous C-peptide and modulate immune responses in individuals with residual beta cell function beyond the initial 100 days post-diagnosis. SAB BIO will co-fund this investigator-led, randomized, double-blind, placebo-controlled study, which is designed to be harmonized with the ongoing Phase 2b SAFEGUARD trial. SAB-142 is a redosable immunotherapy being developed for autoimmune T1D, designed to target immune cells that destroy pancreatic beta cells, potentially preserving insulin production.